Listen
XGEVA (denosumab), monoclonal antibody
Opinions on drugs -
Posted on
Oct 02 2015
Reason for request
Extension of Inclusion
Minor improvement in the treatment of giant cell tumour of bone that is unresectable or where surgical resection is likely to result in severe morbidity.
» XGEVA now has Marketing Authorisation in the treatment of adults and skeletally mature adolescents with giant cell tumour of bone that is unresectable or where surgical resection is likely to result in severe morbidity.
» It helps to stabilise or reduce the volume of giant cell tumours of bone which are unresectable or resectable at the price of severe morbidity.
» No long-term safety data are available.
Clinical Benefit
| Moderate |
- |
Clinical Added Value
| minor |
- |
Contact Us
Évaluation des médicaments
